Surgical margin width for liver-only colorectal cancer spread
Part of Cancer clinical trials.
This trial tests whether a wider surgical margin (at least 7mm) during liver surgery improves survival and reduces cancer return in patients whose colorectal cancer has spread to the liver but not elsewhere. It aims to remove all visible liver tumors with a safe margin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Able to have daily activities without help (ECOG 0-1)
- Colorectal cancer that has spread to the liver, confirmed by biopsy or other tests
- Primary colorectal tumor already removed or will be removed within 4-6 weeks after liver surgery
- 5 or fewer liver tumors
- No cancer spread outside the liver, or any such spread has been fully removed
- Surgeon believes all liver tumors can be completely removed with a margin of at least 7mm
- Good liver function (Child-Pugh A) and enough remaining liver after surgery (≥30%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two surgical approaches for removing liver metastases from colon cancer: anatomical resection versus nonanatomical resection. It aims to see which approach works better for people whose tumors have certain genetic changes or are on the right side of the colon.
This study looks at whether a combination of clinical factors and genetic tests can better predict early return of cancer in people who had surgery for colorectal cancer that spread to the liver. It may help guide future treatment decisions.
This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.
This study compares three different surgical approaches for patients whose colorectal cancer has spread to the liver. Researchers want to understand which surgical order works best, how it affects quality of life, and the costs involved.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial studies people who have liver metastases from cancers other than colorectal cancer and are undergoing surgery to remove them. It aims to gather data on outcomes after liver resection.
Hear when a new Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.